Stool DNA screening for colorectal neoplasia: Biological and technical basis for high detection rates

Pathology

Volumn 44, Issue 2, 2012, Pages 80-88

  Berger, Barry M ^a,b   Ahlquist, David A ^a,b  

^a Exact Sciences Corporation   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Adenoma detection; Colorectal cancer screening; Stool DNA testing

Indexed keywords

EID: 84858308403     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283502fdf     Document Type: Article

References (67)

1. Gellad ZF, Provenzale D. Colorecal cancer: national and international perspective on the burden of dsease and public health impact. Gastro-enterology 2010; 138: 2177-90.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Centers for Disease Control and Prevention. Vital signs: Colorecal cancers screening, incidence and mortality - United States, 2002-2010. Morb Mortal Wkly Rep 2011; 60: 884-9.
4. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-14. (Pubitemid 39665324)
5. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-70.
6. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-8. (Pubitemid 41096630)
7. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-8. (Pubitemid 30489212)
8. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169-74. (Pubitemid 30489213)
9. Lieberman D. Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology 2010; 138: 2115-26.
10. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102: 89-95.
11. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150: 1-8.
12. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
13. Levin B, Lieberman DA, McFarland B, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US MultiSociety Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58: 130-60. (Pubitemid 351830299)
14. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000; 31: 51-7. (Pubitemid 30054387)
15. Eastwood GL. Gastrointestinal epithelial renewal. Gastroenterology 1977; 72: 962-75. (Pubitemid 8093915)
16. Kamra A, Kessie G, Chen JH, et al. Exfoliated colonic epithelial cells: surrogate targets for evaluation of bioactive food components in cancer prevention. J Nutr 2005; 135: 2719-22. (Pubitemid 43156620)
17. Ahlquist DA, McGill DB, Fleming JL, et al. Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 1989; 63: 1826-30. (Pubitemid 19110625)
18. Elias H, Hyde DM, Mullens RS, Lambert FC. Colonic adenomas: stereol-ogy and growth mechanisms. Dis Colon Rectum 1981; 24: 331-42. (Pubitemid 11053259)
19. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-27.
20. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-62. (Pubitemid 32817013)
21. Loktionov A, O'Neill IK, Silvester KR, Cummings JH, Middleton SJ, Miller R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998; 4: 337-42 (Pubitemid 28122747)
22. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003; 49: 1058-65. (Pubitemid 36751091)
23. Loktionov A. Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int J Cancer 2007; 120: 2281-9. (Pubitemid 46642112)
24. Davies RJ, Freeman A, Morris LS, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002; 359: 1917-9. (Pubitemid 34615772)
25. Zou H, Allawi H, Cao X, et al. Quantification of methylated markers with a multiplex methylation specific technology. Clin Chem 2012; 57: (in press).
26. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol 2005; 14: 183-91. (Pubitemid 41391802)
27. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2006; 15: 1115-9.
28. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010; 29: 189-206.
29. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149: 441-50.
30. Zou H, Taylor WR, Harrington JJ, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009; 136: 459-70.
31. Ahlquist D, Zou H, Domanico M, et al. Next generation stool DNA testing for detection of colorectal neoplasia: early clinical evaluation. Gastroen-terology 2012; 141: (in press).
32. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-74. (Pubitemid 44571966)
33. Zou H, Harrington JJ, Shire AM, et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Bio-markers Prev 2007; 16: 2686-96. (Pubitemid 351196325)
34. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97: 1124-32. (Pubitemid 41511211)
35. Huang Z, Li L, Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 2007; 52: 2287-91. (Pubitemid 47246528)
36. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007; 5: 111-7. (Pubitemid 46096834)
37. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009; 27: 858-63.
38. Glockner SC, Dhir M, Yi JM, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009; 69: 4691-9.
39. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008; 14: 524-31. (Pubitemid 351320817)
40. Jiang X, Harrington JJ, Mahoney DW, et al. Detection of colorectal neoplasia by stool DNA testing: high discrimination with multi-marker quantitation. Gastroenterology 2008; 134 (Suppl 1): A-484.
41. Klaassen CH, Jeunink MA, Prinsen CF, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003; 49: 1185-7. (Pubitemid 36751108)
42. Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenter-ology 2008; 135: 489-98.
43. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6. (Pubitemid 26296693)
44. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoido-scopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-33.
45. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 2251-70.
46. Knoernschild HE. Growth rate and malignant potential of colonic polyps: early results. Surg Forum 1963; 14: 137-8.
47. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 2009; 4: 343-64.
48. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011; 42: 1-10.
49. Hussain FT, Yab TC, Harrington JJ, et al. Noninvasive detection of serrated colorectal polyps by stool assay of methylated vimentin and mutant BRAF genes. Digestive Disease Week, New Orleans, LA, 1-12 May 2010.
50. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154: 22-30.
51. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med 1985; 312: 1422-8. (Pubitemid 15083660)
52. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy offecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993; 269: 1262-7. (Pubitemid 23067429)
53. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) 2011; 102: 1563-71.
54. Zou H, Harrington JJ, Hussain FT, et al. Stool DNA and occult blood for detection of colorectal cancer: complementary markers. Gastroenterology 2009; 136 (Suppl 1): A625.
55. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102: 16368-73. (Pubitemid 41688920)
56. Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008; 3: e3759.
57. Tanzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010; 5: e9061.
58. Ahlquist DA, Tayor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2011; Oct 20: (Epub ahead of print).
59. Kisiel JB, Ahlquist DA. Stool DNA screening for colorectal cancer: opportunities to improve value with next generation tests. J Clin Gastro-enterol 2010; 45: 301-8.
60. Byers T. Examining stools for colon cancer prevention: what are we really looking for? Cancer Prev Res (Phila) 2011; 4: 1531-3.
61. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104: 739-50.
62. US National Institutes of Health. ClinicalTrials.gov. Multi-Target Color-ectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer (DeeP-C). 2011 (cited November 2011). http://www.clinicaltrials.gov/ct2/show/NCT01397747?term=Deep-C&rank=1 identifier: NCT0139774
63. Kisiel JB Yab TC, Hussain FTH, et al. Noninvasive detection of colorectal neoplasia in inflammatory bowel disease by stool DNA testing: a pilot study 2010. Digestive Disease Week, New Orleans, LA, 1-12 May 2010.
64. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcera-tive colitis? A population based case control study. Gut 1998; 42: 711-4. (Pubitemid 28261062)
65. Ahlquist DA, Cameron AJ, Jett J, et al. Universal detection of aerodigestive cancers by assay of nonapoptotic human DNA in stool. Gastroenterology 2000; 118 (Suppl 2): A40.
66. Zou H, Harrington JJ, Taylor WR, et al. Pan-detection of gastrointestinal neoplasms by stool DNA testing: establishment of feasibility. Gastroenter-ology 2009; 136 (Suppl 1): A625.
67. Hwang C, Kumar S, Yab TC, et al. Noninvasive detection of intraductal papillary mucinous neoplasms (IPMN) and early stage cancer of the pancreas with stool DNA testing. Gastroenterology 2011; 149 (Suppl): S-10